The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Open accessAbstract
BACKGROUND: Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels of hematologic measures but does not treat the underlying systemic disease. METHODS: We conducted two prospective phase 2 trials in which patients with atypical hemolytic-uremic syndrome who were 12 years of age or older received eculizumab for 26 weeks and during long-term extension phases. Patients with low platelet counts and renal damage (in trial 1) and those with renal damage but no decrease in the platelet count of more than 25% for at least 8 weeks during plasma exchange or infusion (in trial 2) were recruited. The primary end points included a change in the platelet count (in trial 1) and thrombotic microangiopathy event-free status (no decrease in the platelet count of >25%, no plasma exchange or infusion, and no initiation of dialysis) (in trial 2). RESULTS: A total of 37 patients (17 in trial 1 and 20 in trial 2) received eculizumab for a median of 64 and 62 weeks, respectively. Eculizumab resulted in increases in the platelet count; in trial 1, the mean increase in the count from baseline to week 26 was 73×10(9) per liter (P<0.001). In trial 2, 80% of the patients had thrombotic microangiopathy event-free status. Eculizumab was associated with significant improvement in all secondary end points, with continuous, time-dependent increases in the estimated glomerular filtration rate (GFR). In trial 1, dialysis was discontinued in 4 of 5 patients. Earlier intervention with eculizumab was associated with significantly greater improvement in the estimated GFR. Eculizumab was also associated with improvement in health-related quality of life. No cumulative toxicity of therapy or serious infection-related adverse events, including meningococcal infections, were observed through the extension period. CONCLUSIONS: Eculizumab inhibited complement-mediated thrombotic microangiopathy and was associated with significant time-dependent improvement in renal function in patients with atypical hemolytic-uremic syndrome. (Funded by Alexion Pharmaceuticals; C08-002 ClinicalTrials.gov numbers, NCT00844545 [adults] and NCT00844844 [adolescents]; C08-003 ClinicalTrials.gov numbers, NCT00838513 [adults] and NCT00844428 [adolescents]).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Atypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Self-citationThe Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Self-citationComplement regulators and inhibitory proteins
Zipfel, P. F., & Skerka, C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2620 · Cited by 1,264
Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02210310 · Cited by 1,042
Self-citationRother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Caprioli, J., Noris, M., Brioschi, S., Pianetti, G., Castelletti, F., Bettinaglio, P., Mele, C., Bresin, E., Cassis, L., Gamba, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-007252 · Cited by 732
Self-citationFremeaux-Bacchi, V., Fakhouri, F., Garnier, A., Bienaimé, F., Dragon-Durey, M.-A., Ngo, S., Moulin, B., Servais, A., Provot, F., Rostaing, L., et al. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04760512 · Cited by 714
Self-citationAtypical hemolytic uremic syndrome
Loirat, C., & Frémeaux-Bacchi, V. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-60 · Cited by 669
Self-citationBrodsky, R. A., Young, N. S., Antonioli, E., Risitano, A. M., Schrezenmeier, H., Schubert, J., Gaya, A., Coyle, L., de Castro, C., Fu, C.-L., et al. (2008) · Blood · doi:10.1182/blood-2007-06-094136 · Cited by 652
FRETS‐VWF73, a first fluorogenic substrate for ADAMTS13 assay
Kokame, K., Nobe, Y., Kokubo, Y., Okayama, A., & Miyata, T. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05420.x · Cited by 606
Kelly, R. J., Hill, A., Arnold, L. M., Brooksbank, G. L., Richards, S. J., Cullen, M., Mitchell, L. D., Cohen, D. R., Gregory, W. M., & Hillmen, P. (2011) · Blood · doi:10.1182/blood-2011-02-333997 · Cited by 526
Self-citationUse of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
Self-citationEculizumab for Congenital Atypical Hemolytic–Uremic Syndrome
Gruppo, R. A., & Rother, R. P. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0809959 · Cited by 275
Le Quintrec, M., Zuber, J., Moulin, B., Kamar, N., Jablonski, M., Lionet, A., Chatelet, V., Mousson, C., Mourad, G., Bridoux, F., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12077 · Cited by 268
Self-citationRinder, C. S., Rinder, H. M., Smith, B. R., Fitch, J. C., Smith, M. J., Tracey, J. B., Matis, L. A., Squinto, S. P., & Rollins, S. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118195 · Cited by 213
Complement and the atypical hemolytic uremic syndrome in children
Loirat, C., Noris, M., & Frémeaux‐Bacchi, V. (2008) · Pediatric Nephrology · doi:10.1007/s00467-008-0872-4 · Cited by 206
Self-citationNew insights into postrenal transplant hemolytic uremic syndrome
Zuber, J., Le Quintrec, M., Sberro-Soussan, R., Loirat, C., Frémeaux-Bacchi, V., & Legendre, C. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.155 · Cited by 196
Self-citationLiver-Kidney Transplantation to Cure Atypical Hemolytic Uremic Syndrome
Saland, J. M., Ruggenenti, P., & Remuzzi, G. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008080906 · Cited by 165
Self-citationComplement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome
Mache, C. J., Acham‐Roschitz, B., Frémeaux‐Bacchi, V., Kirschfink, M., Zipfel, P. F., Rödl, S., Vester, U., & Ring, E. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01090209 · Cited by 148
Plasmatherapy in Atypical Hemolytic Uremic Syndrome
Loirat, C., Garnier, A., Leclerc, A.-L. S., et al. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1262890 · Cited by 102
Self-citationManagement of hemolytic uremic syndrome
Loirat, C., Saland, J. M., & Bitzan, M. M. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2011.11.013 · Cited by 102
Self-citationPlatelet-associated complement factor H in healthy persons and patients with atypical HUS
Licht, C. P. B., Pluthero, F. G., Li, L., Christensen, H., Habbig, S., Höppe, B., Geary, D. F., Zipfel, P. F., & Kahr, W. H. A. (2009) · Blood · doi:10.1182/blood-2009-03-205096 · Cited by 82
Self-citationThrombotic microangiopathies: new insights and new challenges
Zipfel, P. F., Heinen, S., & Skerka, C. (2010) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32833aff4a · Cited by 52
Wilson, C. H., Torpey, N., Jaques, B. C., Strain, L., Talbot, D., Manas, D., & Goodship, T. H. J. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.04.008 · Cited by 22
Self-citation
Research works printed but not linked: 8
- 10.1016/j.molimm.2012.10.044 · doi:10.1016/j.molimm.2012.10.044
- 10.1097/MNH.0b013e3283378f25 · doi:10.1097/mnh.0b013e3283378f25
- 10.1007/s00431-009-1039-4 · doi:10.1007/s00431-009-1039-4
- 10.1053/j.ajkd.2011.11.027 · doi:10.1053/j.ajkd.2011.11.027
- Chatelet V, 2009, Am J Transplant, 11, 2644, 10.1111/j.1600-6143.2009.02817.x · doi:10.1111/j.1600-6143.2009.02817.x
- 10.1056/NEJMc1001060 · doi:10.1056/nejmc1001060
- 10.1111/j.1600-6143.2012.04252.x · doi:10.1111/j.1600-6143.2012.04252.x
- 10.1097/TP.0b013e3181ccd80d · doi:10.1097/tp.0b013e3181ccd80d
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Rana (2019) · doi:10.1161/circresaha.118.313276 · Cited by 2,095
Atypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Self-citationSyndromes of Thrombotic Microangiopathy
George, J. N., & Nester, C. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1312353 · Cited by 1,279
Metadata
- Authors
- Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp, T., Fouque, D., Furman, R. R., Gaber, O., Herthelius, M., Hourmant, M., Karpman, D., Lebranchu, Y., Mariat, C., Menne, J., Moulin, B., Nürnberger, J., Ogawa, M., Remuzzi, G., Richard, T., Sberro-Soussan, R., Severino, B., Sheerin, N. S., Trivelli, A., Zimmerhackl, L. B., Goodship, T., & Loirat, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-06-06
- Volume
- 368
- Issue
- 23
- Pages
- 2169-2181
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118510193
- Cited by
- 1,586
- References
- 25
- FWCI
- 65.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.